Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of 13.11 CNY, which corresponds to a dynamic price-to-earnings ratio of 17 times for 2025 [4][5]. Core Insights - The company experienced a revenue of 2.144 billion CNY in 2024, representing a year-on-year growth of 31.16%, while the net profit decreased by 6.38% to 274 million CNY [1]. - The company's OTC channel revenue has significantly increased, surpassing the prescription channel, supported by the growth of core products such as the "Kaitoujian" spray [3]. - The company is expected to achieve revenue growth rates of 16.9%, 16.0%, and 14.9% for the years 2025 to 2027, with net profit growth rates of 15.3%, 18.2%, and 17.2% respectively [4]. Financial Performance Summary - In Q1 2025, the company reported a revenue of 409 million CNY, a decline of 3.18% year-on-year, and a net profit of 42 million CNY, down 25.16% [1]. - The sales revenue from respiratory system medications reached 1.455 billion CNY in 2024, marking an 11.89% increase, with significant progress in the coverage of the "Kaitoujian" product [2]. - The company has established a nationwide OTC direct sales network, enhancing its market presence and operational efficiency [3]. Future Projections - The company forecasts a steady increase in revenue and net profit over the next few years, with projected revenues of 2.508 billion CNY in 2025 and 2.909 billion CNY in 2026 [9][10]. - The net profit is expected to rise to 316 million CNY in 2025 and 373 million CNY in 2026, indicating a positive growth trajectory [9][10].